# lung adenocarcinoma (LUAD) - minimax-m3

- Benchmark system: raw
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 3468
- Completion tokens: 6401
- Reasoning tokens: 
- Total tokens: 9869
- API requests reported: 
- Elapsed seconds: 40.926
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: MiniMax

---
<think>Let me carefully analyze this prognostic analysis dataset for lung adenocarcinoma (LUAD) with overall survival (OS) as the endpoint.

First, let me examine the data structure:
- This is a PROGNOSIS analysis
- Comparison: overall survival (OS)
- Tissue: lung adenocarcinoma tumor tissue

The dataset contains genes with:
- HR (Hazard Ratio)
- P value
- FDR

I need to separate genes into:
- Risk-associated genes (HR > 1)
- Protective-associated genes (HR < 1)

Looking at the data, I notice something very concerning about the input data quality:

1. Many genes have extraordinarily high HR values (e.g., 5.1847055e+21) which is biologically implausible
2. P values of exactly 0 are also problematic
3. Many of these genes appear to be:
   - Y-chromosome or testis-specific genes (RBMY1F, FAM9A, TCP10L3, RBMY2AP, CDY10P, USP9YP3, TEX13A, TTTY4C)
   - Pseudogenes (HMGN2P39, ATP5PBP2, RAP1BP2, RNY1P3, DRAXINP1, MTND1P1, etc.)
   - LincRNAs of uncertain function (many RP11-* entries)
   - Unmapped Ensembl entries
   - Mitochondrial pseudogenes

These extreme HR values with HR = 5.18e+21 are clearly numerical artifacts, likely from:
- Very few events in the high-expression group
- Separation issues in survival curves (perfect separation)
- Computational artifacts in Cox regression
- Y-chromosome genes being expressed only in male patients (sex-related confounding)

The "real" prognostic genes with sensible HR values (1.1-1.5 range) include:
- PITX3 (HR=1.43)
- DKK1 (HR=1.48)
- LINC01312 (HR=1.36)
- LINC02178 (HR=1.30)
- VAX1 (HR=1.33)
- TLE1 (HR=1.48)
- KRT6A (HR=1.39)
- FUT4 (HR=1.40)
- RHOF (HR=1.40)
- LDLRAD3 (HR=1.42)
- DKK1, TLE1 are notable

Protective genes (HR < 1):
- RBMXP1 (HR=0.21) - but this is a pseudogene
- CRNDE (HR=0.72)
- CMAHP (HR=0.71)

Now I need to think about what is biologically interpretable:

1. **Y-chromosome/testis genes**: RBMY1F, FAM9A, TCP10L3, RBMY2AP, CDY10P, USP9YP3, TEX13A, TTTY4C, VENTXP7, RHOXF2-related
   - These are likely artifacts from sex differences in the cohort
   - They shouldn't be interpreted as LUAD biology

2. **Pseudogenes and lncRNAs with extreme HRs**: Most of these are likely computational artifacts

3. **Biologically plausible prognostic genes**:
   - DKK1 (Dickkopf-1): Wnt signaling antagonist, known to be involved in cancer progression
   - TLE1: Transducin-like enhancer of split 1, Wnt/Notch signaling
   - PITX3: Paired-like homeodomain transcription factor
   - KRT6A: Keratin 6A, epithelial differentiation
   - FUT4: Fucosyltransferase 4, glycosylation
   - RHOF: Ras homolog family member F, cytoskeleton
   - LDLRAD3: LDL receptor-related
   - VAX1: Ventral anterior homeobox 1

4. **Protective genes**:
   - CRNDE: Colorectal neoplasia differentially expressed (lncRNA)
   - CMAHP: Cytidine monophosphate-N-acetylneuraminic acid hydroxylase pseudogene

Let me think about the biological themes:

1. **Wnt signaling modulation**: DKK1, TLE1 - both involved in Wnt pathway, suggesting Wnt pathway dysregulation is associated with poor prognosis

2. **Epithelial/differentiation programs**: KRT6A, FUT4 - epithelial markers

3. **Developmental transcription factors**: PITX3, VAX1, TLE1 - these are homeobox/transcription factors involved in development, sometimes reactivated in cancer

4. **Sex-chromosome artifact**: Many of the extreme HRs are from Y-chromosome/testis genes which is a major data quality issue

5. **Pseudogene/lncRNA noise**: A large portion of the signal is from pseudogenes and lncRNAs that may not have clear functional roles

Given the data quality issues, I need to be very careful and honest about:
- The numerical artifacts
- The sex-related confounding
- The pseudogene contamination
- The actual biologically interpretable signals

Let me structure my response according to the requirements:

1. Overall biological interpretation
2. Core biological programs (≤5)
3. Key genes/interaction modules (≤10)
4. Validation priorities (≤5)
5. Evidence grounding
6. Limitations and alternative explanations

Let me think more carefully about each:

**Core biological programs:**

Program 1: Wnt signaling dysregulation
- Supporting genes: DKK1 (HR=1.48), TLE1 (HR=1.48)
- DKK1 is a Wnt antagonist; paradoxically, high DKK1 is associated with poor prognosis in many cancers
- TLE1 is a transcriptional co-repressor that interacts with Wnt and other pathways
- Hallmark: Wnt/β-catenin signaling

Program 2: Epithelial differentiation / keratin program
- Supporting genes: KRT6A (HR=1.39), FUT4 (HR=1.40)
- KRT6A is a type II keratin expressed in stratified epithelia and upregulated in some cancers
- FUT4 is involved in fucosylation, Lewis antigen synthesis
- These may indicate a basal/squamous-like differentiation state

Program 3: Developmental transcription factor reactivation
- Supporting genes: PITX3 (HR=1.43), VAX1 (HR=1.33)
- Homeobox genes normally silenced in adult lung
- Reactivation linked to oncogenic programs, EMT, stemness

Program 4: Cytoskeleton/cell motility
- Supporting genes: RHOF (HR=1.40)
- RHOF (Rif) is a Rho GTPase involved in actin dynamics
- Single gene evidence, so weaker program

Program 5: Sex-chromosome / pseudogene artifacts
- Many of the top HRs come from Y-chromosome genes and pseudogenes
- This is likely a confounding effect of sex and survival differences

**Key genes:**

1. DKK1 (HR=1.48) - Wnt antagonist, paradoxically prognostic
2. TLE1 (HR=1.48) - Wnt/Notch transcriptional corepressor
3. PITX3 (HR=1.43) - Homeobox TF
4. KRT6A (HR=1.39) - Keratin
5. FUT4 (HR=1.40) - Fucosyltransferase
6. VAX1 (HR=1.33) - Homeobox TF
7. RHOF (HR=1.40) - Rho GTPase
8. LDLRAD3 (HR=1.42) - LDL receptor family
9. CRNDE (HR=0.72) - Protective lncRNA
10. CMAHP (HR=0.71) - Protective pseudogene

**Validation priorities:**

1. DKK1/TLE1 - Wnt signaling axis in LUAD prognosis
2. KRT6A/FUT4 - Epithelial differentiation subtype
3. Sex-stratified analysis - to address Y-chromosome artifacts
4. CRNDE - protective lncRNA
5. PITX3/VAX1 - developmental TF reactivation

**Limitations:**

1. Many extreme HR values are computational artifacts
2. Sex-related confounding from Y-chromosome genes
3. Pseudogene and lncRNA noise
4. Single-cohort analysis
5. No adjustment for multiple confounders mentioned

Let me write a comprehensive, honest, and biologically grounded response that emphasizes the data quality issues and focuses on the interpretable subset.

Actually, I should be very explicit about the data quality issues - this is critical for proper interpretation. The fact that so many genes have HR = 5.18e+21 (essentially infinite) suggests severe separation issues, very small subgroups, or computational artifacts. These should not be interpreted as biological signals.

The threshold for "biologically interpretable" is probably HR < 10, where we're in a reasonable range for Cox regression coefficients. Anything above that is suspect.

Let me refine my analysis to focus on genes with HR values in a reasonable range (probably 0.5-3 or so), which would include the genes with HRs between 0.21 (RBMXP1 - protective) and about 1.5 (DKK1, TLE1).

I'll structure my response now.</think>

# Prognostic Transcriptomic Interpretation: Lung Adenocarcinoma (LUAD) Overall Survival

## 1. Overall Biological Interpretation

Before describing biological themes, an important data-integrity observation must be flagged. The prognostic table is heavily contaminated with **numerical artifacts**: more than 60 genes carry HR values of ~5.18 × 10²¹ or comparably astronomical magnitudes, paired with P = 0 and FDR = 0. Such HRs are not biologically plausible — they almost certainly reflect **monotone likelihood separation** in Cox regression (i.e., all events in one expression stratum, none in the other), often arising in genes that are expressed in only a handful of patients. A second major source of inflation is **sex-linked confounding**: nearly all "extreme-HR" genes are Y-chromosome or testis-restricted (RBMY1F, FAM9A, TCP10L3, RBMY2AP, CDY10P, USP9YP3, TEX13A, TTTY4C, VENTXP7, DRAXINP1, VAX1 is not Y-linked but co-clusters with these) or are unprocessed pseudogenes/lincRNAs (HMGN2P39, RAP1BP2, RNY1P3, MTND1P1, ATP5PBP2, etc.) or unmapped Ensembl entries. **These rows should not be treated as biological LUAD prognostic signals.**

Within the **biologically interpretable subset** (HR roughly 0.7–1.5, FDR ≤ 0.001), the prognostic signal in this dataset converges on a small, internally coherent picture:

- **Wnt-pathway / β-catenin modulation** (DKK1, TLE1, with VAX1 as a possible Wnt-adjacent homeobox factor).
- **Reactivation of developmental / homeobox transcription factors** otherwise silent in adult lung epithelium (PITX3, VAX1, supported by TLE1 as a transcriptional corepressor).
- **A basal / squamous-like epithelial differentiation state** marked by keratins and fucosylation enzymes (KRT6A, FUT4).
- **Cytoskeletal / Rho-GTPase motility effectors** (RHOF).
- A modest **protective tail** (CRNDE, CMAHP), the latter of which is also a known artifact-prone pseudogene and warrants caution.

The dominant emergent theme is that **poor-prognosis LUAD tumors are enriched for transcriptional programs associated with non-canonical developmental reactivation, Wnt modulation, and basal-epithelial differentiation**, rather than for classical immune or proliferative "Hallmark" signatures — although the latter are absent here because the dataset has been pre-filtered to genes with independent prognostic association, not to pathway-enrichment genes.

---

## 2. Core Biological Programs

### Program A — Wnt / β-catenin signaling modulation (risk-associated)
- **Direction:** Higher expression → worse OS.
- **Major supporting genes:** DKK1 (HR ≈ 1.48), TLE1 (HR ≈ 1.48). VAX1 (HR ≈ 1.33) and ITGB1-DT (HR ≈ 1.30) are contextual.
- **Best-fit pathway:** Hallmark "Wnt/β-catenin signaling"; Reactome "signaling by WNT"; GO:0016055 Wnt signaling pathway.
- **Why this program is supported:** DKK1 is a secreted Wnt antagonist whose overexpression is paradoxically a poor-prognosis marker in many carcinomas (it is thought to shape a Wnt-low, YAP/EMT-favorable niche). TLE1 is a Groucho/TLE family transcriptional corepressor that quashes Wnt, Notch, and FGF effector programs; its overexpression can reflect re-wired transcriptional repression in tumor cells. The convergence of two independent Wnt-axis genes on risk is meaningful.
- **Strength / limitations:** Modest; based on only two named protein-coding genes. Both genes have alternative roles (DKK1 in bone metastasis, TLE1 in synovial sarcoma translocation). The HRs (~1.4–1.5) are real but small. Not driven by a single pathway-database result.

### Program B — Developmental / homeobox transcription-factor reactivation (risk-associated)
- **Direction:** Higher expression → worse OS.
- **Major supporting genes:** PITX3 (HR ≈ 1.43), VAX1 (HR ≈ 1.33), TLE1 (HR ≈ 1.48; also a cofactor), LDLRAD3 as a contextual marker.
- **Best-fit pathway:** GO:0003700 DNA-binding transcription factor activity; Reactome "transcriptional regulation by RUNX" or "homeobox transcription factors" (non-specific).
- **Why this program is supported:** PITX3 and VAX1 are paired-like and emx/vex-like homeobox transcription factors with very restricted normal adult-lung expression. Their ectopic expression in LUAD implies a **lineage-inappropriate developmental program** being reactivated, which has been linked in other carcinomas to stem-like, EMT-prone, or chemoresistant states. TLE1 acts as a co-repressor that would modulate these factors' transcriptional output.
- **Strength / limitations:** Three weakly independent genes with HR 1.3–1.5. No direct protein-interaction evidence provided in the input. VAX1 sits in a genomic neighborhood with several flagged extreme-HR rows, raising the possibility of local co-expression artifacts; this is worth scrutinizing.

### Program C — Basal / squamous-like epithelial differentiation (risk-associated)
- **Direction:** Higher expression → worse OS.
- **Major supporting genes:** KRT6A (HR ≈ 1.39), FUT4 (HR ≈ 1.40).
- **Best-fit pathway:** Hallmark "epithelial-mesenchymal transition" (adjacent); KEGG "Glycosphingolipid biosynthesis" / Reactome "fucosylation" (for FUT4); GO:0008544 epidermis development.
- **Why this program is supported:** KRT6A is a stress/regeneration keratin typically found in basal and squamous epithelia; its expression in LUAD reflects basal-lineage identity, which in lung adenocarcinoma is associated with worse outcome and a more mesenchymal phenotype. FUT4 (fucosyltransferase 4) produces Lewis-X and selectin-ligand structures implicated in adhesion, invasion, and immune evasion. Together they paint a picture of a tumor adopting a basal/squamous-like phenotype.
- **Strength / limitations:** Two named genes only. The "Hallmark" association is indirect (LUAD basal subtype overlaps with EMT, but KRT6A is not a canonical EMT marker). Reasonably robust given that basal LUAD has documented prognostic impact in TCGA and independent cohorts.

### Program D — Cytoskeletal / Rho GTPase motility (risk-associated)
- **Direction:** Higher expression → worse OS.
- **Major supporting gene:** RHOF (HR ≈ 1.40).
- **Best-fit pathway:** Reactome "RHO GTPase cycle"; GO:0007266 Rho protein signal transduction.
- **Why this program is supported:** RHOF (Rif) is a Rho-family GTPase that organizes actin at focal adhesions and is implicated in migration and invadopodia formation. Its risk HR is consistent with the broader basal/EMT program.
- **Strength / limitations:** Single-gene program; weakest of the five and **bordering on insufficient evidence** as a standalone program.

### Program E — lncRNA / pseudogene protective tail (protective, low confidence)
- **Direction:** Higher expression → better OS.
- **Major supporting genes:** CRNDE (HR ≈ 0.72), CMAHP (HR ≈ 0.71).
- **Best-fit pathway:** Not clearly assignable; CRNDE has been linked to PI3K/Akt and Wnt contexts in colorectal/ glioma literature.
- **Why this program is supported:** Both have HR < 1 with FDR ~1 × 10⁻⁷ and 6 × 10⁻⁷ respectively. They represent the only statistically credible protective signals in the table.
- **Strength / limitations:** CMAHP is a pseudogene (sialic-acid hydroxylase–like) and its signal may reflect a structural/regulatory variant rather than a functional transcript. CRNDE is a better-established lncRNA, but its role in LUAD is not well characterized. Overall a **supported but exploratory** program.

---

## 3. Key Genes and Interaction Modules

| # | Gene | HR (direction) | Role in core programs | Interaction type / caveat |
|---|---|---|---|---|
| 1 | **DKK1** | 1.48 (risk) | Program A (Wnt antagonist paradox) | No direct interaction claimed; pathway co-membership with Wnt effectors; literature evidence of DKK1–Wnt axis in multiple carcinomas (independent of dataset). |
| 2 | **TLE1** | 1.48 (risk) | Programs A and B | Documented physical interaction with TCF/LEF and Hes1 (Wnt, Notch) — *protein-interaction evidence* in external literature; co-expression with VAX1 in this dataset is plausible but not evidence of physical interaction. |
| 3 | **PITX3** | 1.43 (risk) | Program B (developmental TF) | No physical interaction claim; transcript-level co-occurrence with VAX1/TLE1 in this dataset. |
| 4 | **KRT6A** | 1.39 (risk) | Program C (basal differentiation) | Co-membership with other keratins in cytoskeletal-intermediate-filament pathway; co-expression with FUT4 implied by shared program. |
| 5 | **FUT4** | 1.40 (risk) | Program C (fucosylation/glycosylation) | Pathway co-membership with FUT3/5/6; no direct physical interaction with KRT6A. |
| 6 | **VAX1** | 1.33 (risk) | Programs A and B | Genomic neighborhood overlap with multiple extreme-HR entries raises flag of co-expression artifact; warrants check. |
| 7 | **RHOF** | 1.40 (risk) | Program D (Rho GTPase) | Pathway co-membership with RAC1, CDC42 family; no direct interaction with other listed genes. |
| 8 | **LDLRAD3** | 1.42 (risk) | Adjunct to Program B | LDL-receptor family member; mechanistic role in LUAD unclear — *insufficient evidence* to elevate. |
| 9 | **CRNDE** | 0.72 (protective) | Program E | Literature evidence of CRNDE binding to PRC2 / interacting with PI3K-Akt in other cancers — *protein/regulatory interaction evidence* from external sources, not from this dataset. |
| 10 | **CMAHP** | 0.71 (protective) | Program E (with caveats) | Pseudogene; protective HR may reflect linked genetic variation rather than transcript function — *insufficient evidence* for mechanism. |

**No gene–gene direct physical interaction is supported by the dataset itself.** Where I describe relationships, they are explicitly *pathway co-membership*, *co-expression in this dataset*, or *literature-supported regulatory interaction* — not new physical interactions inferred from these data.

---

## 4. Validation Priorities

### Priority 1 — DKK1 / TLE1 axis as a prognostic Wnt signature (Mechanistic hypothesis + Biomarker)
- **Why prioritized:** Two independent Wnt-axis genes with the same risk HR (~1.48) is the strongest *non-artifact* signal in the dataset.
- **Evidence in dataset:** Both reach FDR ≤ 4 × 10⁻⁵ with HR ~1.48; convergence is non-trivial.
- **External evidence:** DKK1 overexpression is a published poor-prognosis marker in NSCLC (IHC and serum studies); TLE1 protein overexpression has been documented in lung carcinomas and is a known synovial-sarcoma translocation partner.
- **Next step:** Validate by IHC for DKK1 and TLE1 in an independent LUAD TMA, stratify by stage, and assess whether a combined "DKK1-high / TLE1-high" subgroup has shorter OS. Test in a sex-adjusted model.
- **Confidence label:** **Supported hypothesis** (not established; not exploratory either).

### Priority 2 — Basal / squamous-like (KRT6A + FUT4) subtype as prognostic biomarker (Biomarker)
- **Why prioritized:** Aligns with the recognized but still prognostic-relevant basal-LUAD subtype in TCGA.
- **Evidence in dataset:** Two genes with HR ~1.4 from independent functional classes (cytoskeleton vs. glycosylation) reduce the chance of single-gene artifact.
- **External evidence:** KRT6A is part of published basal-LUAD signatures; FUT4 fucosylation is implicated in selectin-mediated metastasis.
- **Next step:** Score these two genes in TCGA-LUAD RNA-seq, confirm with an external cohort (e.g., CPTAC, MSK-IMPACT LUAD), and check overlap with the recently described "LUAD basal-inflammatory" subtype.
- **Confidence label:** **Supported hypothesis**.

### Priority 3 — PITX3 / VAX1 homeobox reactivation (Mechanistic hypothesis)
- **Why prioritized:** These are normally silent in adult lung; their ectopic expression is mechanistically interesting and could indicate lineage-plasticity biology.
- **Evidence in dataset:** HR 1.33–1.43, FDR < 1 × 10⁻⁵; co-directionality with TLE1.
- **External evidence:** Sparse for LUAD specifically, though homeobox reactivation is documented in other carcinomas.
- **Next step:** Examine promoter methylation / open-chromatin status of PITX3 and VAX1 in LUAD vs. normal lung; ChIP-seq for enhancer marks (H3K27ac) overlapping their loci.
- **Confidence label:** **Exploratory hypothesis**.

### Priority 4 — Sex-stratified re-analysis to remove Y-chromosome artifacts (Confounding or composition check)
- **Why prioritized:** A large fraction of the top-HR list is Y-chromosome and testis-restricted transcripts. This is almost certainly a sex-cohort confound (LUAD prognosis is sex-modulated) rather than LUAD biology. Any downstream signature must not be dominated by these rows.
- **Evidence in dataset:** Genes such as RBMY1F, FAM9A, RBMY2AP, CDY10P, USP9YP3, TEX13A, TTTY4C all carry extreme HRs and are Y-linked; many pseudogenes with extreme HRs are similarly X- or Y-linked.
- **Next step:** Re-run Cox models adjusting for sex and ideally removing all genes mapping to chrY, then check whether any "real" signal from the Y-list survives, it almost certainly will not.
- **Confidence label:** **Established methodological caution** (the artifact itself is established; the conclusion that those genes are *not* LUAD prognostic is supported).

### Priority 5 — CRNDE as protective lncRNA (Mechanistic hypothesis + Biomarker)
- **Why prioritized:** Only robust protective signal with a plausible biological handle.
- **Evidence in dataset:** HR 0.72, FDR ~1 × 10⁻⁷.
- **External evidence:** CRNDE has documented roles in colorectal and glioma biology; LUAD-specific role is under-studied.
- **Next step:** Assess CRNDE expression in paired tumor/normal LUAD, test association with molecular subtypes and immune infiltrate, and probe mechanism (PRC2 recruitment, metabolic regulation).
- **Confidence label:** **Exploratory hypothesis**.

---

## 5. Evidence Grounding

| Claim | Evidence type(s) | Independence |
|---|---|---|
| DKK1/TLE1 are risk-associated in LUAD | Direct (this dataset, HR ~1.48, FDR < 4 × 10⁻⁵) + literature (NSCLC IHC) | Largely independent — dataset signal is statistical, literature is mechanistic/pathway-based. |
| KRT6A/FUT4 mark basal/squamous-like state | Direct (this dataset) + pathway/ontology (keratin, glycosphingolipid biosynthesis) + disease-association (LUAD basal subtype in TCGA) | Partly overlapping (the TCGA basal signature was used to *define* the concept that the dataset is now echoing). |
| PITX3/VAX1 reactivation is prognostic | Direct (this dataset, HR 1.33–1.43) + pathway/ontology (homeobox TFs) | Largely independent of dataset but *insufficient* LUAD-specific external evidence. |
| Y-chromosome genes are artifacts | Direct (extreme HRs paired with chrY/testis identity) + tissue-specific evidence (testis-restricted expression in GTEx) | Strongly independent — sex-specific expression is well documented. |
| CRNDE is protective | Direct (HR 0.72, FDR ~1 × 10⁻⁷) + literature (other cancers) | Limited — only one named protective gene of moderate effect in this dataset. |
| RHOF as motility effector | Direct (this dataset, HR 1.40) + pathway (Rho GTPase cycle) | Single-gene; **insufficient evidence** to elevate beyond a contextual mention. |

No major conflicts between sources are apparent for the named protein-coding genes. **Conflicts are silent rather than explicit:** the absence of canonical immune/proliferative Hallmark genes from the top list may simply reflect the analytical filter, not their lack of prognostic relevance.

---

## 6. Limitations and Alternative Explanations

1. **Severe numerical instability in the Cox fits.** Dozens of HRs of 5.18 × 10²¹ indicate monotone likelihood separation. These rows are not usable as biological signals and must be excluded or robust-fit before any further modeling. **How to check:** rerun with penalized Cox (e.g., `coxnet`) or Firth's correction; visualize Kaplan–Meier curves for the top genes; compute event counts per expression stratum.

2. **Sex / cohort confounding via Y-chromosome transcripts.** LUAD prognosis differs by sex, and many extreme-HR rows are testis/Y-linked. Without sex adjustment, sex is leaking into the gene-level signal. **How to check:** sex-stratified Cox, sensitivity analyses after removing chrY genes, comparison of effect sizes between male- and female-dominated cohorts.

3. **Tumor purity, stromal, and immune composition.** Many flagged "risk" genes (KRT6A, FUT4, RHOF) are epithelial/migratory; "protective" CRNDE is in part immune-context-dependent in other tumors. Without deconvolution (e.g., ESTIMATE, CIBERSORTx), these associations may reflect microenvironment composition rather than tumor-cell-intrinsic biology. **How to check:** include purity/ESTIMATE scores as covariates, run cell-type-specific expression analyses.

4. **Pseudogene and unannotated-lincRNA inflation.** Roughly half of the table entries are pseudogenes or unprocessed lincRNAs (often with the largest HRs). These are prone to alignment artifacts and incidental co-expression with nearby protein-coding genes (e.g., VAX1 neighborhood). **How to check:** verify genomic mapping, check for tandem duplicates of paralogous protein-coding genes, recompute on uniquely-mapped reads.

5. **Single-cohort prognostic model, no external validation, no adjustment for stage / treatment / smoking.** The reported HRs are unadjusted in the input; in LUAD, stage, smoking, EGFR/KRAS status, and adjuvant chemotherapy dominate OS. The gene-level signals could partially proxy for these. **How to check:** multivariable Cox with stage and key mutations; replication in TCGA-LUAD, CPTAC, and an Asian cohort (where LUAD genomics differ).

6. **Association-vs-causation ambiguity.** None of the reported HRs establish mechanism. DKK1, TLE1, KRT6A, FUT4, and the homeobox TFs are plausible drivers based on literature, but the current dataset alone cannot distinguish causative prognosticators from bystanders of a more fundamental subtype.

---

**Bottom line.** Once the data-integrity issues are stripped away, this LUAD OS prognostic dataset tells a coherent but limited story: **poor-prognosis LUAD tumors in this cohort are enriched for a Wnt-modulating, homeobox-TF-reactivating, basal/squamous-like differentiation program**, with CRNDE as a candidate protective factor. The strongest *non-artifactual* leads for follow-up are **DKK1 + TLE1** and **KRT6A + FUT4**. The largest single limitation is not biological — it is the survival-analysis methodology that generated the extreme HRs, which must be corrected before any clinical-translational interpretation is built on these rankings.
